Drug intelligence / Profile preview

bifidobacterium longum NCC 2705

Development stage: Preclinical
Lead developer: Nestlé
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

**Bifidobacterium longum NCC 2705** is a specific strain of *Bifidobacterium longum*, a Gram-positive, non-motile, anaerobic probiotic bacterium that naturally resides in the human gastrointestinal tract[5]. NCC 2705 is notable for producing a **serine protease inhibitor (serpin)**, which inhibits pancreatic and human neutrophil elastases, thereby potentially protecting gut tissue from inflammation and host proteases[3][7]. This strain has demonstrated **immunomodulatory effects**, including attenuation of gluten-induced immunopathology and reduction of enteric nerve activation[2][3][7]. As a probiotic, B. longum NCC 2705 contributes to gut health by regulating inflammation, improving glucose metabolism, reducing cholesterol, and possibly modulating pain in conditions like irritable bowel syndrome[2][3]. It has also been studied for its role in metabolic disorders, including metabolic syndrome, and may help restore microbiota balance and improve barrier function in the intestine[2][6].

Other names: B. longum NCC 2705

Targets

ELANE (Human Neutrophil Elastase)PE (Phosphatidylethanolamine)

Beyond the preview

Go deeper on bifidobacterium longum NCC 2705.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bifidobacterium longum NCC 2705.

Explore the full profile